Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood
flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from
dividing so they stop growing or die. Combining thalidomide and celecoxib with etoposide and
cyclophosphamide may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and celecoxib
with etoposide and cyclophosphamide in treating patients who have relapsed or refractory
malignant glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Celgene National Cancer Institute (NCI) Schering-Plough